FFRct vs Imbio PHA (4.0.0)
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent in the broader cardiovascular imaging AI space but serve distinct clinical purposes. HeartFlow FFRct focuses on diagnosing coronary artery disease by analyzing blood flow in coronary arteries from CCTA scans, while Imbio PHA (4.0.0) assesses pulmonary embolism and hypertension by measuring cardiac structures from CTPA scans.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
HeartFlow FFRct Analysis is designed to aid in diagnosing coronary artery disease by assessing blood flow and identifying areas of narrowing in coronary arteries. Imbio PHA (4.0.0) is intended to assess potential right ventricular dilation from CT pulmonary angiogram (CTPA) scans, assisting in the diagnosis and risk stratification of pulmonary embolism and hypertension.
HeartFlow FFRct Analysis utilizes CCTA (Coronary CT Angiography) scans to create personalized 3D models and analyze blood flow. Imbio PHA (4.0.0) processes CTPA (CT Pulmonary Angiogram) scans to automatically measure cardiac structures.
HeartFlow FFRct Analysis generates personalized 3D digital models of coronary arteries, analyzes blood flow, and provides FFRct values to identify hemodynamically significant lesions. Imbio PHA (4.0.0) provides automated measurements of right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculates RV/LV and PA/Ao ratios, along with annotated DICOM images and PDF summary reports.
No, HeartFlow FFRct Analysis is for patients with suspected or known coronary artery disease, primarily serving Cardiology and Radiology. Imbio PHA (4.0.0) is for patients requiring assessment for pulmonary embolism and hypertension, serving Cardiology, Pulmonology, and Radiology.